T Nohara Selected Research

soyasaponin III

8/2000

Effects of triterpenoids from Pueraria lobata on immunohemolysis: beta-D-glucuronic acid plays an active role in anticomplementary activity in vitro.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

T Nohara Research Topics

Disease

3	Neoplasms (Cancer) 10/2001 - 01/2000
3	Breast Neoplasms (Breast Cancer) 04/2001 - 01/2000
2	Pain (Aches) 03/2001 - 11/2000
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 02/2018
1	Obesity 03/2011
1	Body Weight (Weight, Body) 03/2011
1	Headache (Headaches) 01/2002
1	Flushing 01/2002
1	Atherosclerosis 10/2001
1	Hemolysis 08/2000
1	Adenocarcinoma 01/2000

Drug/Important Bio-Agent (IBA)

2	Monoterpenes (Monoterpenoids)IBA 03/2001 - 11/2000
2	AlkaloidsIBA 03/2001 - 11/2000
1	Testosterone (Sustanon)FDA Link 02/2018
1	CholesterolIBA 03/2011
1	geniposidic acidIBA 03/2011
1	Triglycerides (Triacylglycerol)IBA 03/2011
1	asperulosideIBA 03/2011
1	Polystyrenes (Polystyrene)IBA 03/2011
1	Chlorogenic AcidIBA 03/2011
1	Nonesterified Fatty Acids (NEFA)IBA 03/2011
1	Antihypertensive Agents (Antihypertensives)IBA 03/2011
1	AcetaldehydeIBA 01/2002
1	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2001
1	IsoflavonesIBA 04/2001
1	incarvillateineIBA 03/2001
1	Formaldehyde (Formol)FDA Link 03/2001
1	Cyclin D1IBA 01/2001
1	Analgesics (Analgesic Drugs)IBA 11/2000
1	actinidineIBA 11/2000
1	Complement System Proteins (Complement)IBA 08/2000
1	sophoradiolIBA 08/2000
1	soyasapogenol BIBA 08/2000
1	SaponinsIBA 08/2000
1	kaikasaponin IIIIBA 08/2000
1	soyasaponin IIIIBA 08/2000
1	soyasaponin IIBA 08/2000
1	ergostaneIBA 03/2000
1	GlycosidesIBA 03/2000
1	nuatigeninIBA 03/2000
1	SurvivinIBA 01/2000
1	Cyclin-Dependent Kinase Inhibitor p27IBA 01/2000

Therapy/Procedure

2	Therapeutics 02/2018 - 01/2001